DENVER, Jan. 5 /PRNewswire/ -- Pharmatech, Inc. announces the launch of a new campaign, Pharmatech 2.0, to highlight the company's focus in oncology, along with other key company developments that will take place in early January 2009. The next generation of Pharmatech will feature a name change from Pharmatech, Inc. to Pharmatech Oncology, Inc., as well as a new web site and emerging roles and responsibilities of the executive leadership team.
With the start of 2009, all business will be managed under the name Pharmatech Oncology, Inc. The Pharmatech Board of Directors implemented the name change from the parent company of Pharmatech, Inc. to the subsidiary name of Pharmatech Oncology. Anders Malm, current President, states, "There was a need in the marketplace for better recognition of what type of business Pharmatech was involved in. Changing from Pharmatech to Pharmatech Oncology relays a core understanding that Pharmatech works within the cancer arena."
The leadership team at Pharmatech Oncology will also be undergoing a transformation in roles and titles. Current Chief Executive Officer, Matthew B. Wiener, PharmD, will now take over the daily business operations under the title Chairman and Chief Operating Officer. Anders Malm, current President, will now replace Dr. Wiener as CEO. Pharmatech Oncology also welcomes Rob Bohacs as the new Corporate Development Manager.
Pharmatech Oncology will also introduce a new web site, http://www.pharmatechoncology.com. The launch of the new web site will showcase a more functional format, along with easy navigation capabilities. The current web site http://www.pharmatech.com will point to the new address at http://www.pharmatechoncology.com.
About Pharmatech Oncology:
Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.
Source: Pharmatech, Inc.